Digital channels continue to be a key focus for 2014, but as pharma continues to look ahead to a digital future is there more we can do to enhance the impact of digital strategies?
This free webinar will examine how digital strategy decision making has evolved and present examples, both good and bad, from the industry’s current approach, before examining how you build a digital strategy that's fit for the future.
It will also encompass Hall & Partners research showing the high expectations pharma's customer have of digital sales and communications technology and how they associate it with more interactivity and innovation.
Despite these findings physicians feel tablet detailing (‘t-detailing’) is not having a greater impact than traditional paper-based
So, given the huge potential for getting closer to our customers and tailoring our interactions with them the research begs the question, what more should we be doing with digital?
The webinar will also explore how evidence-based decision making can enhance the digital strategy for your brand.
Speakers from Hall & Partners and digital communications agency Ebee will discuss how decision making currently informs digital strategies, what learnings can be drawn from experience to date and explore how pharma companies could optimise their investments in digital.
RecordedMar 12 201460 mins
Your place is confirmed, we'll send you email reminders
Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.
Over the past 12 months several new products have been approved for a wider range of tumour types and with pipelines boasting numerous other products in the area, competition looks set to hot up.
On November 17 Research Partnership, in association with PMGroup, will host a free webinar which will explore the key features of the immuno-oncology market and the critical success factors for remaining competitive.
I would like to invite you to register for the webinar - either to watch it live on the day or for access to a recorded version.
Most life sciences companies know they need to move their multichannel marketing forward, but that requires managing a greater volume of tactics that need to be developed, approved, implemented, and measured.
And of course, those tactics must reflect how their target audiences engage in content – such as the 65% of healthcare professionals who say they prefer clinical summaries.
To truly transform the commercial model, companies must have a strategic blueprint that combines business objectives with brand goals to determine the appropriate resource levels and channel attribution.
On November 9 Aptus Health, in association with PMGroup, will explore three essential ingredients for transforming the commercial model and driving success:
• Learn how to deploy multichannel marketing at scale through integrated campaigns that reach millions of HCPs across specialties, languages, and markets
• Gain insights into your target HCPs’ behaviours - and how to leverage those insights to make your campaigns more effective
• Explore results from a recent survey of European HCPs revealing their preferences for the types of online medical education, as well as the resources they find most helpful in their daily practice
Commercial analytic solutions are becoming more and more common within the Pharma industry. Companies are spending millions implementing tools which are aimed at helping users identify opportunities to improve the bottom line, segment customers, track multichannel campaign success and meet a myriad of other objectives. Despite all the 'perceived' value these tools can add, they remain largely unused. Excuses for the lack of adoption are varied but can generally be classified into one of three areas - they are either too complex, it isn't convenient to use or it just doesn't deliver on the value promised. These issues are compounded by the fact that they are generally only identified when the solution has been deployed and expected to be used. By ensuring that these issues are addressed at all stages during the development and not just when adoption targets are not being met, commercial analytic solutions can be exploited to attain the anticipated value and more.
Traditional models of cognitive behaviour remain meaningful, but they can fail to deliver strong links between ‘smart’, cognitive-based factors of judgement and the decision-making associated with actual behaviour change.
In contrast, behavioural economics accounts for the ‘lazy’ judgments and thoughts that occur at an automatic level, but can over-weight the prevalence of such behaviour.
On October 4 Cello Health Insight, in association with PMGroup, will host a free webinar on applying adaptive and integrated behavioural models to qualitative enquiry.
It will look at how to achieve a better understanding of what drives therapeutic decision-making and how medical marketing, digital and PR initiatives can change future behaviours in favour of achieving target sales.
Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.
On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.
It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.
Medical education has the potential to affect a significant number of healthcare professionals’ (HCPs) clinical practice and so improve patients’ outcomes.
Nonetheless, achieving these goals requires medical education to move beyond didactic message delivery - that only improves HCPs’ awareness - to using many multi-channel educational interventions to drive real behaviour change.
In this webinar, Lucid will discuss why, as an industry, we should all be moving beyond our internal goals to think about how we can improve patient outcomes with all our programmes and share a process for creating measurable improvements.
In recent years pharma has slowly been realising the importance of customer experience and the fact that the commercial model that served it so well for the past 30 years might not be the right one for the future.
But continued ‘evolution’ is no longer acceptable - a more revolutionary approach to customer engagement design that makes it easy for front line employees to engage andmakes it relevant and unique for the customer is needed before it is too late.
On 19 May EY, in association with PMGroup, will host a free webinar on customer engagement design in pharma and time to move beyond the rhetoric, and I would like to invite you to register for it - either to watch it live on the day or for access to a recorded version.
Companies developing new rare disease treatments face several unique challenges when it comes to their regulatory and reimbursement submissions.
One of the most pressing of these is the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs), which form an important part of assessing signs and symptoms of rare diseases and treatment response.
Recent global survey data confirms that pharmaceutical sales representatives are still doctors’ preferred source of pharmaceutical product information. Although doctors are increasingly using social media and other online channels in their professional capacity to search for and share information, face-to-face interactions still carry more trust and are more likely to influence prescribing. While pharma shouldn’t neglect digital channels as potentially valuable entry points for the promotion of assets, more meaningful and impactful marketing strategies will be those that pursue an optimal mix of face-to-face and digital initiatives.
What does ‘authenticity’ mean to the healthcare sector and how can companies best build authentic relationships with their stakeholders?
For the past few years FleishmanHillard has researched the concept of authenticity and how the ‘authenticity gap’ between expectations and experience can impact the reputation of a company or sector.
This work has produced nine drivers of reputation, which provide actionable insights for companies seeking to manage their reputation more effectively.
On 24 November this PMGroup webinar, in association with FleishmanHillard, will draw on the latest UK research, with additional examples from Canada, Japan and Germany, and provide practical examples of how to remain authentic in an inauthentic world.
I would like to invite you to register for this webinar - either to watch it live on the day or for access to a recorded version.
Medical technologies should be innovative, unique, and have technical feasibility and robust intellectual property. This does not, however, guarantee successful market access and reimbursement.
Despite companies striving to improve patient care, many still struggle to gain market access - governed by three main factors: evidence requirements, the reimbursement landscape and defining clinical and economic value for medical devices.
On 18 November Adelphi Values and two expert speakers, in association with PME, will explain these multiple challenges and discuss key considerations, potential challenges and solutions for gaining successful market access for often life-changing medical technologies.
I would like to invite you to register for this webinar - either to watch it live on the day or for access to a recorded version.
In an ever-changing healthcare environment, the need to prove value for money remains a key focus for payers and reimbursement decision makers.
New pricing regulations, broad-based healthcare reforms, tendering processes and an increased emphasis on value-based assessment are all changing the game for pricing and launch sequencing, while raising hurdles for market access.
There’s no one-size-fits-all approach when it comes to defining value to meet the specific healthcare needs of national, regional and local payers, but it’s never been more critical to customising your value propositions in order to optimise reimbursement and patient access.
So on 22 September this Adelphi Values webinar, in association with PMGroup, will focus on value evidence considerations by payer archetypes.
There is growing momentum and recognition among researchers, regulatory agencies, policy makers and payers towards a more patient-centric approach to health outcomes research, including development and validation of Clinical Outcome Assessments, and participation of patients in clinical trials.
On 25th June 2015 at 3pm (GMT) PMGroup, in association with Adelphi Values, will host a free webinar that shows how a more patient-centered approach can be used to enhance outcomes research and conduct of clinical trials, providing examples from research in oncology and inflammatory disease.
The webinar will also demonstrate the importance of patient engagement at all stages of PRO development and will include direct feedback from a patient advisor, so you can learn about their experience as a partner in the research process.
Advances in KOL Intelligence are delivering richer insights into clinical landscapes than ever before. The pharmaceutical organisations which harness these insights to inform strategic planning will be better able to meet the challenges of an increasingly competitive and complex environment for KOL Engagement. There’s a wealth of information out there, but it’s not all about Big Data – it’s about smart data and insight that you can easily act on.
Is your KOL Intelligence a mass of data, or is it a tool that broadens your understanding of influence and helps you make smarter decisions? Can you confidently identify who’s suitable for ad boards? Are your network maps simply impressive graphics, or a tool for better engagement? Or are you new to KOL intelligence and looking for guidance on where to begin?
As the pioneers of KOL mapping and the UK's leading KOL intelligence agency, we believe the strength of our work doesn't simply lie in the quality of our research, but in how we help our clients understand it. If you’re new to KOL intelligence we’d like to show you what you can learn. And if you already know how valuable it is, you’ll understand how important it is to stay on top of the latest trends in KOL analysis.
On May 13th, at 12pm (GMT), in association with PMLiVE, Kendle Healthcare will host a free webinar, “Next-generation KOL Intelligence: Better insight, better outcomes”, which will help you understand how to use KOL intelligence to make better-informed decisions. Our webinar will be interactive and we welcome any questions you may have.
There is no doubt that the processes and capabilities that pharma organizations need to employ have evolved. Since the creation of the UK's clinical commissioning groups (CCGs), the early development and implementation of a holistic market access solution based on local clinical and payer insight has become even more crucial.
But how do we clearly define a market access journey that brings together the right mix of activities? What is the optimum time to begin engaging with stakeholders? How do we address the difficult balance between doing everything that payers ask for and doing enough so that relevant data are built into trial design, and outcomes are captured during the development process? What do payers really want to see?
These questions will be tackled on 10 December at 2pm (GMT), PMLiVE, in association with Quintiles, will be hosting a free webinar to examine when to begin developing a local value story, and engaging with payers at an earlier point, so you get a holistic understanding of the patient pathway.
UK payer perspectives: market access and the importance of early stakeholder engagement will feature Ryan Wooller, Director of Market Access and Service Innovation, Commercial UK at Quintiles and Dr Junaid Bajwa, a GP and board member for Greenwich CCG
The webinar and Q and A is free, so register now to watch it live on the day or access the recorded version at a later date.
As pharma grapples with the need to become more doctor- and patient-centric, can co-creation help it better engage and connect with its audience by redefining industry relationships with physicians and improve patient care?
On 4 December, when M3 and their partners at Abundance, in association with PMGroup, will look at what co-creation could mean for pharma and bring to life what it could produced.
They will demonstrate how they have put this approach into practice to enhance and improve product development and marketing for brands like Doctors.net.uk, the BBC and NSPCC.
The presentations will be followed by a Q&A session for viewers to find out more about how co-creation works and how it could benefit their business.
Register for the webinar now - either to watch it live on the day or for access to a recorded version.
Reach is one thing, trust is another. Digital channels may well be are growing in reach, but recent research from Cello Health Insight found that when it comes to trust, doctors value face-to-face interactions with peers, KOLs and sales reps as sources of information with the greatest influence on their decision to prescribe. The digital space presents big opportunities, yet it remains to some extent the new frontier for pharma marketers, who have a big responsibility to understand it and get it right.
Join us to hear the findings from the Digital Health Debate – an international study examining which digital channels are being used by doctors and why. The findings show the digital channels most likely to influence treatment decisions and where they should sit in the overall marketing mix. The session will also explore what digital tools can be used by marketers and business intelligence teams to understand digital challenges and to measure their effectiveness.
On 5 November at 2pm (GMT) there will be a free webinar dedicated to the implications of Big Data and the opportunity it provides for every market access stakeholder within the UK.
'UK payer perspectives: Is big data the future of market access?’ will feature Paul Sutton, Director of Outcomes and Value, Commercial UK at Quintiles and Dr Junaid Bajwa, a GP and board member for Greenwich CCG.
Take part in this exclusive webinar where they discuss the big issues in big data and its impact on market access and real world outcomes.
Live webcasts for executives in pharmaceutical, biotech, healthcare
This is a new service from PMGroup, who will be known to many in the pharmaceutical and healthcare industries for its well established portfolio of publications, awards schemes, live events and online offerings. Join us on our webinars to get connected with other thought leaders in healthcare